US4445887A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
Assignee: Thomas Jefferson University
•
Filing: 1982-09-30
•
Granted: 1984-05-01
•
Expires: 2002-09-30
Abstract
Abstract A novel acute care cerebral support system and method for treating severly ischemic brains is disclosed wherein an oxygenated nutrient emulsion is circulated through at least a portion of the ventriculo-subarachnoid spaces. The nutrient emulsion contains an oxygenatable non-aqueous component, an aqueous nutrient component, an emulsification component, and other components which render physiologic acceptability to the nutrient emulsion. The disclosed system and method have been shown to effectively exchange oxygen, carbon dioxide, glucose, and other metabolites in severely stroked brains. Significant restoration of oxidative metabolism and electrographic activity result from the disclosed treatment. Methods for producing the nutrient emulsion and a system for delivering that emulsion to the cerebrospinal pathway are also disclosed. Additionally, novel diagnostic methods for diagnosing the physiologic state of hypoxic-ischemic and other diseased neurologic tissue during treatment are provided.
Inventors
- 👤 Jewell L. Osterholm
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 10:57
CPC Classifications
A; A61; A61M; A61M3/00; A61M3/02; A61M3/0204; A61M3/0212; A61M2202/00; A61M2202/04; A61M2202/0464; A61M2202/0468; A61M2202/0476; A61M2205/00; A61M2205/36; A61M2205/3653; A61M2210/00; A61M2210/06; A61M2210/0693
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
106 words
A method of treating hypoxic-ischemic neurologic tissue, in mammals, comprising: (a) providing a physiologically acceptable oxygenated fluorocarbon emulsion capable of transferring oxygen to hypoxic-ischemic neurologic tissue contacted thereby; (b) injecting a substantially continuous stream of said fluid into the cerebrospinal fluid pathway at a first injection point; (c) substantially continuously withdrawing fluid from said cerebrospinal fluid pathway at a second point which is selected to create a circulation of said oxygenated fluorocarbon emulsion in the vicinity of said hypoxic-ischemic tissue, said circulation being sufficient to support significant aerobic respiration of a portion of said hypoxic-ischemic tissue; whereby hypoxic-ischemic neurologic tissue will be oxygenated by said fluid.
Claim 2
Independent Claim
106 words
A method of treating hypoxic-ischemic neurologic tissue, in mammals, comprising: (a) providing a physiologically acceptable oxygenated fluorocarbon emulsion capable of transferring oxygen to hypoxic-ischemic neurologic tissue contacted thereby; (b) injecting a substantially continuous stream of said fluid into the cerebrospinal fluid pathway at a first injection point; (c) substantially continuously withdrawing fluid from said cerebrospinal fluid pathway at a second point which is selected to create a circulation of said oxygenated fluorocarbon emulsion in the vicinity of said hypoxic-ischemic tissue, said circulation being sufficient to support significant aerobic respiration of a portion of said hypoxic-ischemic tissue; whereby hypoxic-ischemic neurologic tissue will be oxygenated by said fluid.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein said first point is within a cerebral ventricle.
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein said first point is within the lateral ventricle.
Claim 5
Dependent Claim
14 words
The method of claim 1 wherein said second point is within a subarachnoid space.
Claim 6
Dependent Claim
14 words
The invention of claim 4 wherein said subarachnoid space is a spinal subarachnoid space.
Claim 7
Dependent Claim
16 words
The invention of claim 5 wherein said spinal subarachnoid space is a lumbar spinal subarachnoid space.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein said second point is within a cerebral cistern.
Claim 9
Dependent Claim
13 words
The invention of claim 5 wherein said cerebral cistern is the cisterna magna.
Claim 10
Dependent Claim
20 words
The method of claim 1 wherein said fluid is injected at a rate of between 1 ml/minute and 200 ml/minute.
Claim 11
Dependent Claim
37 words
The method of claim 9 wherein said fluid is withdrawn at a rate which selected to maintain the hydraulic pressure of said fluid with the CSF pathway at between about 25 mm and 250 mm of water.
Claim 12
Dependent Claim
36 words
The method of claim 1 wherein said fluid is injected at a rate of between about 20 ml/min/100 gms of ischemic-hypoxic neurologic tissue to be treated and 60 ml/min/100 gms of said tissue to be treated.
Claim 13
Dependent Claim
19 words
The method of claim 11 wherein said injection rate is about 45-60 ml/min/100 gms of tissue to be treated.
Claim 14
Dependent Claim
22 words
The method of claim 1 wherein said fluid is injected at a hydraulic pressure which does not exceed 250 mm of water.
Claim 15
Dependent Claim
14 words
The invention of claim 1 wherein said first point is within a subarachnoid space.
References Cited (Backward Citations)
US3482575A
Cited
US3516410A
Cited
US3583387A
Cited
US3626950A
Cited
US3669116A
Cited
US3669094A
Cited
US3690323A
Cited
US3946731A
Cited
US3753865A
Cited
US3823091A
Cited
US3941119A
Cited
US3989843A
Cited
US3894541A
Cited
US4163734A
Cited
US4148314A
Cited
US4173654A
Cited
US4173224A
Cited
US4110474A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-01 | 1987-10-31 | 1988-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-01 | 1991-10-31 | 1992-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-01 | 1995-10-31 | 1996-05-01 | $7700.00 | Window Closed / Lapsed |